Episode 163: The Uromigos Debate – Treatment of favorable risk renal cancer

David McDermott attempts to get his point across…again.

Related Episodes

Episode 181: Relapsed Germ Cell Tumors
Episode 168: Mechanisms of response to PD1 therapy in renal cancer
Episode 167: Highlights from EIKCS oral session
Episode 150: Comparing the quality of life data in renal trials
Episode 149: Treatment-free survival for ipilimumab and nivolumab
Episode 147: Toni Choueiri Renal Cancer Christmas Special
Episode 117: PD1/VEGF adverse event management in renal cancer
Episode 140: Ipilimumab in renal cancer
Episode 135: The STAR Study
Episode 138: Renal Cancer ESMO Guidelines Update